Clinical results reveal new opportunities and setbacks in rare disease and cancer care, shaping treatment strategies and future regulatory decisions.
|Articles|February 1, 2013
- BioPharm International-02-01-2013
- Volume 26
- Issue 2
BioPharm International, February 2013 Issue (PDF)
Viral Vaccines
Advertisement
Articles in this issue
over 13 years ago
Assessing Development Needs for Biobetters and Biosimilarsover 13 years ago
Facility Design and Operation: A Primerover 13 years ago
Offering a Biopharma View of Social Mediaover 13 years ago
GMP Compliance Becomes Prominent Enforcement Issueover 13 years ago
Therapeutic Antibodies in Reviewover 13 years ago
The Vaccine Sceneover 13 years ago
Automated Concentration and Diafiltration of Multiple siRNA Samplesover 13 years ago
End of the Dedicated CMO?over 13 years ago
Viral Vaccine Manufacturingover 13 years ago
Navigating Emerging Markets: Eastern EuropeAdvertisement
Related to this article
Phase 3 interim data for RYZ101, the lead asset from Bristol Myers Squibb’s $4.1 billion RayzeBio deal, meet the primary endpoint.
Efzimfotase alfa missed significance on the six-minute walk test in adolescents and adults, while the FDA review of the therapy proceeds toward 2027.
Odyssey's 146-patient phase 2a trial will pair OD-001 with vedolizumab, targeting both innate and adaptive immune drivers of ulcerative colitis.
MT027, T-MAXIMUM's B7-H3 CAR-T therapy, earns a second FDA-cleared phase 2 trial, now testing lung and breast cancer brain metastases.
New clinical data highlight improved disease control, reduced eye bulging, and weight-loss benefits, potentially broadening options for patients with unmet needs.
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Bristol Myers Squibb's Nathan Pennell explains how the MRD endpoint supports accelerated approval in multiple myeloma without changing how clinicians monitor patients.
Advertisement
Advertisement